U.K. ratchets up antidepressant warnings

Following the FDA's lead, U.K. regulators have upgraded warnings on all antidepressants to include an increased risk of suicidal thoughts and behavior among young adults taking the meds.

The Medicines and Healthcare Regulatory Agency checked out the FDA's review of safety data, and then concluded that the risk of suicidality was higher in young people. And, the agency said, the risk was the same "across the different antidepressant classes," so labels will be revised not only on SSRIs like Paxil and Prozac, but on other antidepressants such as Effexor and Wellbutrin.

- check out the MHRA's release
- read the item at Pharmalot

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.